The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Chronic inflammation can contribute to the development and instability of atherosclerotic plaque in artery walls, raising cardiovascular risk over time. It is not, by itself, a guarantee of heart disease, and the clearest pathway described by current consumer and government sources is arterial plaque—not a universal, direct progression of heart-muscle damage.
What chronic inflammation does to the heart and blood vessels over time
Inflammation is part of the immune system’s response to injury or infection. A short-lived response can help protect the body; inflammation that persists for months or years can harm healthy tissue. The American Heart Association (AHA) explains that scientists are still working to identify exactly where cardiovascular-disease-related inflammation occurs and how immune pathways differ among people.
As an Amazon Associate I earn from qualifying purchases.
In arteries, inflammation interacts with other risks as atherosclerosis develops. Smoking, high blood pressure, and LDL cholesterol can injure artery walls and contribute to plaque buildup. Immune cells gather at affected areas, and immune activity may contribute to plaque growth or instability. NHLBI describes inflammation and blood lipids as interacting parts of this process, rather than inflammation acting alone.
Free tools Windows power users keep installed
One-click scans. No signup required.
Over time, plaque can narrow an artery or become unstable. If plaque ruptures, a clot may form; a resulting blockage can interrupt blood flow to the heart or brain. The possible outcome is an acute event after a process that may have developed over years.
#1 Best Overall
- Avery publishing group
- Language: english
- Book - prevent and reverse heart disease: the revolutionary, scientifically proven, nutrition-based cure
How inflammation affects plaque in the arteries
Atherosclerosis is the buildup of fatty plaque in artery walls. The AHA’s explanation describes a sequence in which cardiovascular risks injure the vessel lining, plaque accumulates, and immune cells respond at the site. That immune response can contribute to enlargement or instability of the affected area.
NHLBI’s November 12, 2024 feature says immune danger signals may increase plaque size and trigger events that make plaque more likely to rupture. It also notes that researchers are still studying the pathways involved. This does not mean everyone with chronic inflammation develops plaque or cardiovascular disease, nor that inflammation is the only cause.
Rank #2
As Peter Libby, M.D., a cardiovascular medicine specialist at Brigham and Women’s Hospital and Mallinckrodt Professor of Medicine at Harvard Medical School, told NHLBI: “Inflammation is the common theme from the beginning to the end of atherosclerosis and across many conditions.” The observation describes inflammation’s role across the disease process; it does not establish that inflammation alone initiates or determines an individual’s outcome.
Can inflammation cause a heart attack or stroke?
Inflammation can contribute to the arterial disease that leads to a heart attack or ischemic stroke, but it is not accurate to say that inflammation alone directly causes either event. A heart attack can occur when a coronary artery supplying the heart is blocked. An ischemic stroke can occur when an artery in or leading to the brain is blocked. Plaque and clots are among the mechanisms that can produce those blockages.
Rank #3
The sources describe this arterial pathway more clearly than they establish a single direct route from chronic inflammation to progressive damage of the heart muscle. NHLBI discusses heart failure and inflammatory research, but that is not evidence that chronic inflammation universally causes heart-muscle damage. The risks and pathways vary by person.
How doctors measure inflammation related to heart disease
High-sensitivity C-reactive protein (hsCRP) is a marker associated with cardiovascular risk. An AHA professional toolkit summarizing a 2025 American College of Cardiology scientific statement quotes this recommendation: “Universal screening of hsCRP in both primary and secondary prevention patients, in combination with cholesterol, presents a major clinical opportunity and is therefore recommended.” This is a recommendation reproduced in a professional toolkit; it is not a diagnosis of the cause of inflammation or individualized advice to obtain a test.
Risk assessment belongs in the broader clinical picture, alongside cholesterol and other relevant factors. A test result should be interpreted by a health professional; the cited guidance does not establish consumer self-testing as a way to diagnose or prevent cardiovascular disease.
What the evidence does—and does not—say about reducing risk
NHLBI’s November 2024 feature says lower levels of chronic inflammation “have been shown to curb cardiovascular disease risks in some people by about 20-30%.” The feature does not identify the underlying study or define the population for that estimate, so it should not be read as an expected benefit for any one person.
Best Value
Inflammation is one part of cardiovascular risk. The AHA identifies smoking, high blood pressure, and LDL cholesterol as modifiable contributors to artery injury and plaque. Managing established risks remains important; the sources do not support treating inflammation as a substitute for that care.
NHLBI discusses colchicine and other anti-inflammatory approaches as areas of treatment and research, including the need to target pathways carefully. Decisions about medication—including anti-inflammatory drugs or cholesterol-lowering treatment—should be made with a clinician. These sources do not establish supplements as a treatment for inflammation-related cardiovascular risk.
Quick Recap
Sources and scope
- American Heart Association, “Inflammation and Heart Disease,” last reviewed January 11, 2024.
- National Heart, Lung, and Blood Institute, “Immune function, inflammation, and cardiovascular disease,” November 12, 2024.
- American Heart Association, “hsCRP: Toolkit for Professionals,” summarizing a 2025 ACC scientific statement.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
